Board approves enabling resolution to explore raising up to Rs. 600 crore
Orchid Pharma's Board met on October 20, 2026 and approved an enabling resolution to explore options for raising funds.
By ScoutQuest · · 2 min read
- Indicative fund raise size
- up to Rs. 600 Crores (Rupees Six Hundred Crore Only)
- Board meeting date
- October 20, 2026
What the Board approved
The Board of Directors of Orchid Pharma Ltd met on October 20, 2026 and approved, as an 'Enabling Resolution', a proposal to explore the available market opportunities for raising funds, in the best interest of the Company.
How the funds may be raised
- By issue of equity shares or any other eligible securities or instruments.
- Including fully or partly convertible debentures.
- Through a qualified institutions placement, private placement, public issue of equity shares and/or debt securities, preferential issue, or any other permissible mode.
- Or any combination of the above, as may be considered appropriate.
Size of the plan
The update describes an indicative amount of up to Rs. 600 Crores (Rupees Six Hundred Crore Only).
What an enabling resolution means
An enabling resolution gives the Board the authority to explore and act on a fund raise. It sets the outer boundary (here, up to Rs. 600 Crores) and the possible routes. The update states that the required information on the total number of securities or the exact amount is not available as on date.
The route actually chosen, the price, and the number of securities are decided when a specific issue is taken up, which is why the Board's approval is described as enabling.
Approvals involved
- Such statutory and regulatory approvals as may be required.
- The approval of the members of the Company, wherever applicable.
- Other approvals, permissions and consents as may be necessary.
Points for retail investors to track
- Which mode is finally used (for example, preferential issue, QIP or convertible debentures) and on what terms.
- Whether members are asked to vote on the proposal, and the details placed before them at that stage.
- Any change in the share count that the chosen route would bring, since that affects existing shareholders' holding.
Also from Orchid Pharma
Orchid Pharma signs licensing and supply agreement with Libra for Exblifep across nine Latin American markets
24 Oct 2026
Board approves enabling resolution to explore raising up to Rs. 600 Crores
20 Oct 2026
Board meeting on October 20, 2026 to consider and evaluate options for raising funds
15 Oct 2026
More numbers
- Indicative amount for fund raisingRs. 600 Crores
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.